Home
SAVA
SAVA News

Latest Cassava Sciences Inc. (SAVA) News on November 19, 2025

Cassava Reports Q3 2025 Financials Results and Provides Business Update

GlobeNewswire

7 days ago

Cassava Reports Q3 2025 Financials Results and Provides Business Update

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

GlobeNewswire

a month ago

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Promising Penny Stocks To Consider In May 2025

Simply Wall St.

6 months ago

Promising Penny Stocks To Consider In May 2025

Cassava Reports Q1 2025 Financials Results, Provides Business Update

GlobeNewswire

6 months ago

Cassava Reports Q1 2025 Financials Results, Provides Business Update

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

GlobeNewswire

7 months ago

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

MT Newswires

7 months ago

Cassava Sciences CMO James Kupiec to Retire

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

GlobeNewswire

7 months ago

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround

Zacks

8 months ago

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround

Is the Future Bleak for SAVA Stock Following Another Setback?

Zacks

8 months ago

Is the Future Bleak for SAVA Stock Following Another Setback?

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Reuters

8 months ago

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More

Zacks

8 months ago

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More

Cassava ends simufilam Alzheimer’s programme after second Phase III failure

Clinical Trials Arena

8 months ago

Cassava ends simufilam Alzheimer’s programme after second Phase III failure

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study

Zacks

8 months ago

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study

MT Newswires

8 months ago

Sector Update: Health Care Stocks Fall Late Afternoon

MT Newswires

8 months ago

Top Midday Decliners

Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program

GuruFocus.com

8 months ago

Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program

MT Newswires

8 months ago

Cassava Sciences' Phase 3 Study of Simufilam Showed No Benefit for Alzheimer's Patients

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

GlobeNewswire

8 months ago

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Cassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right Now

Insider Monkey

8 months ago

Cassava Sciences (SAVA): One of the Best Short-Term Stocks to Buy Right Now

Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

8 months ago

Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?

H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal

TipRanks

8 months ago

H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

MT Newswires

9 months ago

Sector Update: Health Care Stocks Higher Thursday Afternoon

MT Newswires

9 months ago

Cassava Sciences Licenses Simufilam Patent From Yale University for Potential Treatment of Seizures; Shares Rise

Cassava Sciences Licenses Simufilam Method of Treatment Patent

GlobeNewswire

9 months ago

Cassava Sciences Licenses Simufilam Method of Treatment Patent

Cassava Gears Up to Report Q4 Earnings: What's in the Cards?

Zacks

9 months ago

Cassava Gears Up to Report Q4 Earnings: What's in the Cards?

MT Newswires

10 months ago

Cassava Sciences to Reduce Staff, Halt Further Analysis

Cassava Sciences Provides a Business Update

GlobeNewswire

10 months ago

Cassava Sciences Provides a Business Update

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

Zacks

a year ago

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

Zacks

a year ago

A Post-Mortem on Cassava Sciences

SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study

Zacks

a year ago

SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study

Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)

Zacks

a year ago

Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)

MT Newswires

a year ago

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Tuesday; Cassava Sciences to Advance, MicroStrategy to Decline

Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops

Investor's Business Daily

a year ago

Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops

Cassava Sciences plummets over 80% on Alzheimer's trial fail

Yahoo Finance Video

a year ago

Cassava Sciences plummets over 80% on Alzheimer's trial fail

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

Cassava Sciences stock plummets after Phase III Alzheimer’s fail

Clinical Trials Arena

a year ago

Cassava Sciences stock plummets after Phase III Alzheimer’s fail

Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops

FastCompany

a year ago

Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops

Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails

Barrons.com

a year ago

Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Benzinga

a year ago

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study

Investopedia

a year ago

Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study

MT Newswires

a year ago

Sector Update: Health Care Stocks Edge Higher Premarket Monday

Cassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops

Investor's Business Daily

a year ago

Cassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Cassava Sciences Simufilam Misses Endpoints in Late-Stage Alzheimer's Trial; Shares Drop Pre-Bell

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

GlobeNewswire

a year ago

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Cassava Sciences to Hold Corporate Update on November 25th

GlobeNewswire

a year ago

Cassava Sciences to Hold Corporate Update on November 25th

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

GlobeNewswire

a year ago

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?

Zacks

a year ago

Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?

What Makes Cassava Sciences (SAVA) a New Buy Stock

Zacks

a year ago

What Makes Cassava Sciences (SAVA) a New Buy Stock

Cassava Sciences Reports Q3 2024 Financial and Operating Results

GlobeNewswire

a year ago

Cassava Sciences Reports Q3 2024 Financial and Operating Results

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

GlobeNewswire

a year ago

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value

Simply Wall St.

a year ago

Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value

MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain

Benzinga

a year ago

MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain

Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge

Insider Monkey

a year ago

Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge

Cassava Sciences Advances Alzheimer’s Trials Amid SEC Settlement

TipRanks

a year ago

Cassava Sciences Advances Alzheimer’s Trials Amid SEC Settlement

Cassava Sciences: Phase III trials storm ahead amid controversy

Clinical Trials Arena

a year ago

Cassava Sciences: Phase III trials storm ahead amid controversy

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires

a year ago

Cassava Sciences Completes Phase 3 ReTHINK Alzheimer's Trial

What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?

Benzinga

a year ago

What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?

SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

Zacks

a year ago

SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

Company News for Sep 30, 2024

Zacks

a year ago

Company News for Sep 30, 2024

Why Cassava Sciences Stock Dived by Almost 11% Today

Motley Fool

a year ago

Why Cassava Sciences Stock Dived by Almost 11% Today

These Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More

Barrons.com

a year ago

These Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More

Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims

Yahoo Finance Video

a year ago

Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims

MT Newswires

a year ago

Top Midday Decliners

Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims

Investopedia

a year ago

Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims

MT Newswires

a year ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday

Investing.com

a year ago

Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, HP Inc., and More

Barrons.com

a year ago

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, HP Inc., and More

SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty

Benzinga

a year ago

SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty

MT Newswires

a year ago

Update: Cassava Sciences Pays $40 Million to Settle SEC Charges; Shares Drop Pre-Bell

MT Newswires

a year ago

Cassava Sciences Pays $40 Million to Settle SEC Charges

Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims

Bloomberg

a year ago

Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims

Cassava Sciences Resolves SEC Investigation

GlobeNewswire

a year ago

Cassava Sciences Resolves SEC Investigation

Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims

Reuters

a year ago

Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims

Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan

Zacks

a year ago

Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

GlobeNewswire

a year ago

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

MT Newswires

a year ago

Cassava Sciences Names Richard Barry CEO, Appoints Claude Nicaise as Board Chairman

Cassava Sciences Names Rick Barry as Chief Executive Officer

GlobeNewswire

a year ago

Cassava Sciences Names Rick Barry as Chief Executive Officer

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire

a year ago

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

Silicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free Stocks

Insider Monkey

a year ago

Silicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free Stocks

Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?

Simply Wall St.

a year ago

Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?

MT Newswires

a year ago

Cassava Sciences Shares Drop on Estimated $40 Million Charge in H2 to Resolve US SEC Probe

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

GlobeNewswire

a year ago

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

Reuters

a year ago

Biotech firm drops defamation suit against short-sellers after researcher charged

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

GlobeNewswire

a year ago

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

GlobeNewswire

a year ago

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

Cassava Sciences Announces Expansion of Open-Label Extension Trials

GlobeNewswire

a year ago

Cassava Sciences Announces Expansion of Open-Label Extension Trials

MT Newswires

a year ago

Cassava Shares Rise After Incoming Chairman Gives Timeline for Alzheimer's Drug Study Read Out

Why Cassava Sciences Stock Is Skyrocketing Today

Motley Fool

a year ago

Why Cassava Sciences Stock Is Skyrocketing Today

MT Newswires

a year ago

Cassava Sciences Shares Rise After Court Schedules Hearing on Bonus Plan Lawsuit Settlement

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

Zacks

a year ago

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

MT Newswires

a year ago

Sector Update: Health Care Stocks Advance Late Afternoon

Cassava Sciences Faces Leadership Shake-Up, Prioritizes Transparency And Scientific Rigor In Alzheimer's Trials

Benzinga

a year ago

Cassava Sciences Faces Leadership Shake-Up, Prioritizes Transparency And Scientific Rigor In Alzheimer's Trials

MT Newswires

a year ago

Top Midday Decliners

MT Newswires

a year ago

Cassava Sciences Names Richard Barry Executive Chairman, Launches Search for CEO

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

GlobeNewswire

a year ago

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

Cassava forms committee after US probe, researcher fraud

Yahoo Finance Video

a year ago

Cassava forms committee after US probe, researcher fraud

Stocks to Watch Monday: Chewy, Boeing, NIO, Cassava Sciences

The Wall Street Journal

a year ago

Stocks to Watch Monday: Chewy, Boeing, NIO, Cassava Sciences

Share on Social Networks: